SG10201901482XA - Oncolytic adenovirus encoding a b7 protein - Google Patents
Oncolytic adenovirus encoding a b7 proteinInfo
- Publication number
- SG10201901482XA SG10201901482XA SG10201901482XA SG10201901482XA SG10201901482XA SG 10201901482X A SG10201901482X A SG 10201901482XA SG 10201901482X A SG10201901482X A SG 10201901482XA SG 10201901482X A SG10201901482X A SG 10201901482XA SG 10201901482X A SG10201901482X A SG 10201901482XA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- adenovirus
- oncolytic adenovirus
- viruses
- adenovirus encoding
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Abstract
PWO70 O NCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN OR ACTIVE FRAGMENT The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer. (F igure 6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201901482XA true SG10201901482XA (en) | 2019-03-28 |
Family
ID=56008588
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201901482XA SG10201901482XA (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
SG10201803081TA SG10201803081TA (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
SG11201708604TA SG11201708604TA (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803081TA SG10201803081TA (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
SG11201708604TA SG11201708604TA (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Country Status (31)
Country | Link |
---|---|
US (6) | US11000559B2 (en) |
EP (2) | EP3288573B1 (en) |
JP (3) | JP6931229B2 (en) |
KR (3) | KR20240032177A (en) |
CN (2) | CN107690479B (en) |
AU (3) | AU2016256582B2 (en) |
BR (2) | BR112017023171A2 (en) |
CA (1) | CA2984038C (en) |
CL (2) | CL2017002731A1 (en) |
CO (1) | CO2017010831A2 (en) |
CY (1) | CY1122833T1 (en) |
DK (1) | DK3288573T3 (en) |
EA (1) | EA037611B1 (en) |
ES (1) | ES2780366T3 (en) |
HK (1) | HK1249009A1 (en) |
HR (1) | HRP20200439T1 (en) |
HU (1) | HUE048320T2 (en) |
IL (3) | IL284375B (en) |
LT (1) | LT3288573T (en) |
MX (1) | MX2017013684A (en) |
MY (1) | MY183703A (en) |
PE (2) | PE20180241A1 (en) |
PH (1) | PH12017501942A1 (en) |
PL (1) | PL3288573T3 (en) |
PT (1) | PT3288573T (en) |
RS (1) | RS60105B1 (en) |
SA (2) | SA520412637B1 (en) |
SG (3) | SG10201901482XA (en) |
SI (1) | SI3288573T1 (en) |
WO (1) | WO2016174200A1 (en) |
ZA (1) | ZA201801589B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
PT3288573T (en) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
TW201722985A (en) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | CD80 extracellular domain polypeptides and their use in cancer treatment |
AU2016372576A1 (en) * | 2015-12-17 | 2018-06-21 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
PL3436591T3 (en) * | 2016-03-31 | 2023-06-26 | The European Molecular Biology Laboratory | Adenoviral coat protein derived delivery vehicles |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
JP7160482B2 (en) | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Compositions and methods for treating cancer with DUOCAR |
EP3518947B1 (en) * | 2016-09-27 | 2023-07-05 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
WO2018145033A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
US11684637B2 (en) * | 2017-05-25 | 2023-06-27 | University Of Central Florida Research Foundation, Inc. | Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
CA3064863A1 (en) * | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
HUE063274T2 (en) | 2017-06-01 | 2024-01-28 | Akamis Bio Ltd | Oncolytic virus and method |
US11573230B2 (en) * | 2018-01-26 | 2023-02-07 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
US20210040167A1 (en) * | 2018-03-05 | 2021-02-11 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
CA3095427A1 (en) * | 2018-03-30 | 2019-10-03 | Tomoki Todo | Swelling-suppressive oncolytic virus |
WO2020052551A1 (en) * | 2018-09-10 | 2020-03-19 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
KR102503349B1 (en) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
US20220249127A1 (en) * | 2019-05-14 | 2022-08-11 | Oncolys Biopharma Inc. | Method for administering oncolytic virus to tumor tissue, and device for administration |
GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
GB202102049D0 (en) * | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
WO2023180527A1 (en) * | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3405241A1 (en) * | 1984-02-15 | 1985-08-29 | Bayer Ag, 5090 Leverkusen | 1- / 4- (BENZOTHIA- OR -OXAZOL-2-YLTHIO- OR -2-YLOXY) PHENYL / -1,3,5-TRIAZINE-2,4,6- (1H, 3H, 5H) -TRIONE, METHOD FOR THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT |
KR920008907B1 (en) * | 1989-11-28 | 1992-10-10 | 삼성전자 주식회사 | Picture size control circuit |
US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
FR2705361B1 (en) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Viral vectors and use in gene therapy. |
NZ269156A (en) | 1993-07-13 | 1996-03-26 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
CN1242051A (en) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US6420524B1 (en) | 1997-02-20 | 2002-07-16 | Johns Hopkins University School Of Medicine | Gain of function mutations in ATP-dependent transposition proteins |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
CN1110553C (en) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | Gene engineering adenovirus and its application |
WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
CA2678259C (en) * | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
DE60014489T3 (en) | 1999-05-17 | 2010-08-12 | Crucell Holland B.V. | Adenovirus-derived gene transfer vehicles containing at least one type adenovirus type 35 element |
AU5464000A (en) | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
DE60107203T3 (en) * | 2000-01-21 | 2009-07-23 | Biovex Ltd. | HERPES VIRUSES FOR GENE THERAPY |
US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
WO2001092549A2 (en) | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
DE60234496D1 (en) | 2001-01-04 | 2010-01-07 | Goeran Wadell | VIRUS VECTOR FOR GENE THERAPY |
US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
JP2005515784A (en) | 2002-02-01 | 2005-06-02 | トランジェーヌ、ソシエテ、アノニム | Adenoviral vector for modulating cellular activity associated with POD |
US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
CN1705740B (en) * | 2002-10-15 | 2013-07-24 | 佩尔·松内·霍尔姆 | Adenovirus expressing genes in reverse order and use thereof |
US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
WO2004087930A1 (en) | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
JP2007530004A (en) | 2003-07-18 | 2007-11-01 | オニックス ファーマシューティカルズ,インコーポレイティド | Subgroup B adenoviral vectors for treating diseases |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
CA2836987C (en) | 2004-05-26 | 2016-07-05 | Psioxus Therapeutics Limited | Chimeric adenoviruses for use in cancer treatment |
CN100361710C (en) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF |
US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
CN101068933A (en) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
EP1929021A2 (en) | 2005-08-31 | 2008-06-11 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
DE102005055128B4 (en) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viral vector, its use for the treatment of hepatocellular carcinoma and pharmaceutical agents comprising the vector |
ES2304281B1 (en) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | ADENOVIRUS ONCOLITICOS FOR THE TREATMENT OF CANCER. |
CA2673520A1 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
TW200951143A (en) | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
CN101381742A (en) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | Late promoter targeting regulation oncolytic adenovirus pCN305 vector and construction method and application thereof |
ES2385251B1 (en) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | ONCOLYTIC ADENOVIRUSES FOR THE TREATMENT OF CANCER. |
EP2486137B1 (en) * | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
CN107090440B (en) | 2010-08-16 | 2021-10-22 | 萨克生物研究学院 | Adenovirus assembly method |
KR20130138245A (en) * | 2010-09-24 | 2013-12-18 | 온코스 테라퓨틱스 오와이 | Oncolytic adenoviral vectors and methods and uses related thereto |
CA2812093A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
WO2013074507A2 (en) | 2011-11-14 | 2013-05-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
CN102586327B (en) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | D24 fiber protein modified conditionally replicating adenovirus carrier with exogenous gene by one-step method and application of carrier |
WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
EP3653714A1 (en) | 2013-11-22 | 2020-05-20 | DNAtrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
CN107406859A (en) | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | The oncolytic adenovirus of encoding bispecific antibody and relative method and purposes |
PT3288573T (en) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
AU2016372576A1 (en) | 2015-12-17 | 2018-06-21 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
AU2017233072B2 (en) | 2016-03-18 | 2020-12-24 | Nantcell, Inc. | Multimodal vector for dendritic cell infection |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
HUE063274T2 (en) * | 2017-06-01 | 2024-01-28 | Akamis Bio Ltd | Oncolytic virus and method |
GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 PT PT167230432T patent/PT3288573T/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/en unknown
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/en unknown
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en active Application Filing
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/en active Active
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/en active Active
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 PL PL16723043T patent/PL3288573T3/en unknown
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/en unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 EA EA201791971A patent/EA037611B1/en unknown
- 2016-04-29 KR KR1020247006825A patent/KR20240032177A/en active Application Filing
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/en active Search and Examination
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/en unknown
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/en unknown
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/en active Application Filing
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/en active IP Right Grant
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/en not_active Application Discontinuation
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/en active Active
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 RS RS20200325A patent/RS60105B1/en unknown
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/en active Active
- 2016-04-29 SI SI201630679T patent/SI3288573T1/en unknown
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/en active
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/en unknown
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/en unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-30 SA SA520412637A patent/SA520412637B1/en unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/en unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/en unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/en active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-06-20 HK HK18107929.1A patent/HK1249009A1/en unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-17 HR HRP20200439TT patent/HRP20200439T1/en unknown
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/en unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA520412637B1 (en) | Oncolytic adenovirus encoding a b7 protein | |
PH12018501291A1 (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
BR112019001737A2 (en) | pten-long expression with oncolytic viruses | |
MX2019000252A (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides. | |
AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
MX2018006840A (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs). | |
MX2023008067A (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy. | |
BR112018013930A2 (en) | oncolytic virus, virus expressing three heterologous genes, pharmaceutical composition, virus for use, manufacturing product, cancer treatment method, and virus use | |
BR112018008766A2 (en) | variants, compositions and methods and uses of the reduced factor viii cpg for the treatment of hemostasis disorders | |
BR112016020688A2 (en) | COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) | |
EP4043021A3 (en) | Oncolytic tumor viruses and methods of use | |
MX2016014187A (en) | Adenovirus comprising an albumin-binding moiety. | |
BR112019002646A2 (en) | chimeric poxvirus compositions and uses thereof | |
PH12020550117A1 (en) | Variant rnai | |
AR101814A1 (en) | VIRUS FLAVIVIRUS TYPE PARTICLE | |
BR112017002549A2 (en) | iron and sulfur protein group mutations that enhance the use of xylose | |
WO2018060368A3 (en) | Compositions and methods for enhancing the stability of transgenes in poxviruses | |
PH12017500109A1 (en) | Composition for treating cancerous cells and a method therefor | |
BR112017024786A2 (en) | recombinant oncolytic viruses and uses thereof | |
MY185846A (en) | Oncolytic adenovirus encoding a b7 protein | |
EA201890595A1 (en) | ONCOLYTIC ADENOVIRUS, ENCODING B7 PROTEIN | |
CL2017001008A1 (en) | Use of a hpv vaccine composition to treat cancer and skin lesion. | |
EA201791442A1 (en) | METHODS OF TREATMENT OF HEMATOLOGICAL DISTURBANCES, SOLID TUMORS OR INFECTIOUS DISEASES WITH THE USE OF NATURAL CELL-CALLERS | |
AR094912A1 (en) | VACCINE AGAINST THE VIRUS OF BOVINE LEUKEMIA |